Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT) by Paul, Carle et al.
THERAPEUTICS
BJD
British Journal of Dermatology
Transition to ustekinumab in patients with moderate-to-
severe psoriasis and inadequate response to methotrexate:
a randomized clinical trial (TRANSIT)
C. Paul,1 L. Puig,2 K. Kragballe,3 T. Luger,4 J. Lambert,5 S. Chimenti,6 G. Girolomoni,7 J.-F. Nicolas,8 E. Rizova,9
F. Lavie,9 S. Mistry,10 P. Bergmans,11 J. Barker12 and K. Reich,13,14 on behalf of the TRANSIT Investigators*
1Hoˆpital Larrey, Service de Dermatologie, Toulouse cedex 9, 31059, France
2Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, 08025 Barcelona, Spain
3Department of Dermatology,Arhus University Hospital,Arhus Sygehus, 8000Arhus, Denmark
4Department of Dermatology, University of M€unster, D-48149 M€unster, Germany
5Department of Dermatology, Ghent University, 9000 Ghent, Belgium
6Policlinico Universitario Tor Vergata, Clinica Dermatologica, 00133 Rome, Italy
7Clinica Dermatologica, University of Verona, 37126 Verona, Italy
8Hospital Lyon-Sud, Lyon University, 69495 Lyon, France
9Janssen-Cilag 1, rue Camille Desmoulins, TSA 91003, 92787 Issy les Moulineaux, Cedex 9, France
10Janssen, 50-100 Holmers Farm Way, High Wycombe, Bucks HP12 4EG, U.K.
11Janssen-Cilag B.V., Postbus 90240, 5000 LT Tilburg, the Netherlands
12St John’s Institute of Dermatology, King’s College, London SE1 9RT, U.K.
13Dermatologikum Hamburg, Stephansplatz 5, 20354 Hamburg, Germany
14Georg-August-University, G€ottingen, Germany
Correspondence
Carle Paul.
E-mail: paul.c@chu-toulouse.fr
Accepted for publication
19 September 2013
*The members are TRANSIT Investigators pre-
sented in Appendix 1.
Funding sources
This clinical trial was sponsored by Janssen Phar-
maceutica NV. Funding for medical writing sup-
port and assistance in collating author
contributions was provided by Janssen.
Conflicts of interest
See Appendix 2 for details.
Clinicaltrials.gov identifier: NCT01059773.
DOI 10.1111/bjd.12646
Summary
Background Limited data exist on transitioning patients with psoriasis from conven-
tional systemic agents to biologics.
Objectives The TRANSIT study aimed to assess the efficacy and safety of two meth-
otrexate-to-ustekinumab transition strategies.
Methods Patients with moderate-to-severe psoriasis and inadequate methotrexate
response were randomized 1 : 1 to receive ustekinumab with immediate (arm
1) or 4-week gradual (arm 2) methotrexate withdrawal. Patients weighing
≤ 100 kg or > 100 kg received ustekinumab 45 mg or 90 mg, respectively. The
primary endpoint was the frequency of adverse events (AEs) at week 12. Second-
ary endpoints included additional safety, efficacy and patient-reported outcomes.
We report the 12-week efficacy and safety results.
Results Overall, 244 patients in arm 1 and 245 in arm 2 were randomized and
received ustekinumab. Four patients per arm discontinued the trial by week 12.
At week 12 in arms 1 and 2, respectively, 61% and 65% of patients experi-
enced an AE, 29% and 24% had a serious AE, and 12% and 04% had an AE
leading to ustekinumab discontinuation. In arms 1 and 2, respectively, median
Psoriasis Area and Severity Index (PASI) score decreased from 152 and 154 at
baseline to 29 and 28 at week 12; 58% and 62% of patients achieved a 75%
reduction from baseline in PASI score (PASI 75) at week 12; median baseline
Dermatology Life Quality Index fell from 8 and 9 at baseline to 1 (both arms)
at week 16.
Conclusions Ustekinumab was well tolerated and effective in patients who had an
inadequate response to methotrexate. Both transition strategies resulted in similar
week 12 safety and efficacy outcomes.
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What’s already known about this topic?
• In patients with moderate-to-severe psoriasis, biologics are recommended for use
after conventional systemic agents have failed, or in patients for whom they are
not suitable.
• There are limited data on how to transition patients from conventional systemic
treatment to biologics.
What does this study add?
• In patients with an inadequate response to methotrexate, similar efficacy and
safety/tolerability outcomes were observed at week 12 after initiating ustekinumab,
irrespective of whether methotrexate was immediately or gradually withdrawn.
Therefore, immediate transitioning from methotrexate to ustekinumab can be rec-
ommended and a washout period is not needed.
• No adverse safety or efficacy effects were noted after overlapping ustekinumab and
methotrexate treatment for up to 1 month.
In Europe, biological agents are recommended for use in
patients with moderate-to-severe psoriasis after conventional
systemic agents have failed, or in patients with contraindica-
tion to, or intolerance of, conventional therapy.1 Therefore, in
clinical practice, many patients who are started on a biologic
will be receiving a conventional systemic agent, and, theoreti-
cally, there are several approaches that the dermatologist could
use to achieve the transition from one agent to the other.
A ‘washout’ strategy is usually used in phase III clinical tri-
als of biological agents, where it is important to distinguish
the effect of the investigational agent from previously admin-
istered therapy. In the phase III clinical trials PHOENIX 12 and
2,3 patients could not receive systemic therapy within 4 weeks
of ustekinumab initiation. A shorter, 4–17-day washout has
been explored in a small study where patients transitioned
from etanercept, methotrexate or phototherapy to ada-
limumab.4 However, the use of a washout period may not be
practical in clinical practice, as symptoms could worsen during
the ‘no treatment’ phase. Unfortunately, there are few evi-
dence-based clinical data to support other transition strategies.
Two other transition strategies can be used when moving
from conventional systemic to biological therapy. Overlapping
treatment with both agents followed by gradual withdrawal of
conventional therapy may be an appealing option as it pro-
vides continuous coverage with active treatment. Alternatively,
patients could switch immediately from conventional therapy
to the biologic. The TRANSIT (TRrial to Assess Naturalistic
Safety and efficacy outcomes In patients Transitioned to
ustekinumab from previous methotrexate therapy) trial is a
52-week study that aimed to investigate these two approaches
in patients with moderate-to-severe psoriasis. Methotrexate
was selected as the conventional systemic agent as it is widely
used in Europe.1 Patients were transitioned to ustekinumab, a
human monoclonal antibody targeting interleukin (IL)-12 and
IL-23. In patients who were randomized to an overlapping
phase of methotrexate and ustekinumab, a 4-week methotrex-
ate-tapering phase was considered adequate given the rapid
onset of efficacy reported with ustekinumab.5
We describe the primary analysis of the TRANSIT trial; the
primary endpoint was safety at week 12 in patients who tran-
sitioned to ustekinumab using these two strategies. In addi-
tion, efficacy outcomes at week 12 and patient-reported
outcomes at week 16 are reported. The 52-week outcomes of
the study, including the effect of dose adjustment on efficacy,
are presented in a separate article.6
Materials and methods
Patients and study design
TRANSIT was a 52-week, phase IV, open-label, parallel-group,
randomized clinical trial conducted at 86 centres in Europe
and Israel. The study investigators enrolled adult patients with
moderate-to-severe plaque psoriasis (concurrent psoriatic
arthritis was allowed), defined as a Psoriasis Area and Severity
Index (PASI) score ≥ 10 at screening and at the time of first
administration of ustekinumab, and a diagnosis of plaque
psoriasis for ≥ 6 months. Patients had to have an inadequate
response (PASI ≥ 10) to a methotrexate regimen of 10–25 mg
weekly for eight or more consecutive weeks and, in the judge-
ment of the treating physician and patient, required a treat-
ment change. Patients were ineligible if they had an active/
chronic/recurrent infection or recent serious infection, a
history or symptoms of active or latent tuberculosis, a history
of malignancy (except in situ basal or squamous cell skin carci-
noma; treated in situ cervical carcinoma with no evidence of
recurrence; or treated squamous cell skin carcinoma with no
evidence of recurrence within 5 years), or had received treat-
ment with any agent that specifically targeted IL-12 and IL-23,
any biological therapy within 12 weeks, any B/T cell-inhibi-
tory agents (or had evidence of persistent lymphocyte deple-
tion), topical psoriasis treatments (except low-potency topical
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corticosteroids), systemic psoriasis treatments other than
methotrexate, or phototherapy within 2 weeks.
Patients were randomized 1 : 1 to receive ustekinumab
(Stelara; Janssen-Cilag International NV, Beerse, Belgium)
either with immediate withdrawal of methotrexate (arm 1) or
with 4 weeks’ overlap with a tapering methotrexate regimen
(arm 2). Randomization was according to a computer-gener-
ated central schedule prepared by the study sponsor and based
on a minimization with biased-coin assignment method.
Patients were assigned via an interactive voice-response system
and randomization was stratified by site and patient weight
(≤ 100 kg or > 100 kg). Ustekinumab was initiated according
to the European Summary of Product Characteristics,7 with
weight-based doses given subcutaneously at weeks 0, 4, 16,
28 and 40. Patients weighing > 100 kg received ustekinumab
90 mg at each time point; patients weighing ≤ 100 kg received
45 mg initially. In arm 1, the last methotrexate dose was
received during the week before the first ustekinumab injection.
In arm 2, the predefined methotrexate dose-reduction schedule
depended on the dose at screening. For example, patients
receiving methotrexate 25 mg weekly at screening were to
decrease the dose to 20 mg at day 0 and then by 5 mg each
week, whereas those receiving 10 mg weekly at screening were
to reduce this to 5 mg at day 0 and then by 25 mg every
2 weeks. All patients had to stop methotrexate within 7 days
before the second ustekinumab injection (scheduled for week
4) irrespective of the final methotrexate dose. Low-potency top-
ical corticosteroids being taken at stable doses for ≥ 4 weeks
prior to screening could be continued.
In a protocol amendment, an exploratory dose-adjustment
schedule was investigated at weeks 28 and 40, with findings
described elsewhere;6 planned enrolment was also increased
from 500 to 576 to account for premature discontinuations.
The clinical trial protocol was approved by the appropriate
institutional review boards in each participating country, and
the trial was performed in accordance with Good Clinical
Practice. All patients provided written informed consent. The
clinical trial was registered with clinicaltrials.gov
(NCT01059773).
Assessments
Study visits were planned at weeks 0, 2, 4, 12, 16, 28, 40
and 52. Patients underwent physical examination and routine
laboratory testing, including testing for tuberculosis, at screen-
ing. Efficacy evaluations included PASI score (0–72) and the
Physician’s Global Assessment (PGA; 0–5), which were per-
formed at every study visit. In addition to absolute scores,
PASI responses were defined as 50%, 75%, 90% or 100%
reductions from baseline (PASI 50, 75, 90, 100, respectively);
additionally, absolute PASI scores were categorized by PASI
score ≤ 1, ≤ 3 or ≤ 5. Quality-of-life assessments were carried
out at weeks 0, 4, 16, 28 and 52 and included the Dermatol-
ogy Life Quality Index (DLQI),8 EuroQol-5D visual analogue
scale (EQ-5D VAS)9 and Hospital Anxiety and Depression Scale
(HADS).10 Routine safety evaluations included the assessment
of vital signs, treatment-emergent adverse events (AEs), and
standard laboratory investigations. AEs spontaneously reported
by the patient were recorded throughout the trial. Any clini-
cally significant AEs present at the end of the study were fol-
lowed up until clinically stable or resolved. Haematology,
serum chemistry and pregnancy testing were performed by a
central laboratory (Covance, Geneva, Switzerland).
Statistical analyses
The primary endpoint was the proportion of patients experi-
encing one or more AE(s) by week 12 in each treatment arm.
Secondary outcome measures included additional safety, effi-
cacy and patient-reported outcomes at weeks 12 or 16, over
the 52-week trial period, and following exploratory dose
adjustment (reported elsewhere6). No interim analyses were
conducted.
A sample size of 576 patients (288 patients per arm) was
calculated to give ~80% power to detect a significant differ-
ence between treatment arms if there was a 121-fold differ-
ence in AEs, a 20-fold difference in treated infections, and a
41-fold difference in serious AEs (SAEs). The calculation was
based on a two-sided Fisher’s exact test with a type I error
rate of 005, and on safety data from the ustekinumab clinical
development programme. However, the planned sample size
of 576 patients was not reached (489 patients were enrolled,
randomized and received at least one dose of study drug).
Nevertheless, the slight decrease of power associated with this
reduction in the number of patients was considered to be
within acceptable limits because of the low number of drop-
outs observed to week 12.
All assessments were summarized using descriptive statistics.
Efficacy analyses included patients with a valid measurement
(observation) at the relevant time point and excluded patients
who did not have a baseline and at least one postbaseline
observation. Confirmatory last-observation-carried-forward
(LOCF) imputed analyses were performed for some efficacy
endpoints. Formal statistical hypotheses were not prespecified
and statistical comparisons between treatment arms were not
performed.
Results
Patient disposition and baseline characteristics
From 19 October 2009 to 23 August 2010, 649 patients with
moderate-to-severe plaque psoriasis were screened, 490 were
enrolled and randomized, and 489 received at least one dose
of study drug [intent-to-treat population (Fig. S1, Support
Information)]. Planned study enrolment was not reached due
to delays in recruitment that could have put the execution of
the study at risk. Overall, 391 patients (195 in arm 1; 196 in
arm 2) weighed ≤ 100 kg and received ustekinumab 45 mg,
while 98 patients (49 in each arm) weighed > 100 kg and
received the 90-mg dose. Few patients (8; 16%) discontinued
therapy by week 12.
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Patients’ baseline characteristics were well balanced between
treatment arms (Table 1). At baseline, patients had a median
PASI score of 15 (interquartile range 12–20), 25% had a PGA
of 4 or 5 (marked or severe), and 26% had a diagnosis of
psoriatic arthritis. Median DLQI was 8 at baseline, indicating
that the condition had a moderate effect on the patients’ qual-
ity of life.11 Median EQ-5D VAS was 70, slightly lower than
population norms for European countries (72–83),12 and
approximately one-quarter of patients had clinically relevant
anxiety and/or depression according to HADS (HADS ≥ 8).13
Mean methotrexate dose at screening was 145 mg weekly;
59% of patients had previously used methotrexate for
< 1 year, 28% for 1 to < 3 years, and 13% for ≥ 3 years.
Among the 29% of patients who had previously used a bio-
logic, the most common reason for having discontinued it
was lack of efficacy (82 patients; 59%).
Efficacy
Psoriasis Area and Severity Index scores decreased rapidly and
substantially from baseline and were similar at week 12 irre-
spective of the transition strategy used (Fig. 1). A similar pro-
portion of patients in the two treatment arms achieved an
absolute PASI score of ≤ 1, ≤ 3 or ≤ 5 (Fig. 2a) and PASI 50,
75, 90 or 100 responses (Fig. 2b) at week 12. A PGA of 0 or
1 was achieved by most patients [156 of 239 (65%) patients
in arm 1 and 164 of 236 (69%) patients in arm 2] at week
12 irrespective of the transition strategy used. PASI and PGA
scores were similar in confirmatory LOCF analyses (Table 2).
Safety
The safety and tolerability profile of ustekinumab at week 12
was similar irrespective of the transition strategy used (Table 3).
At least one AE was reported for 149 (61%) and 158 (65%)
patients in arms 1 and 2, respectively. The number of patients
with an SAE [seven (29%) and six (24%) patients, respec-
tively] or an AE leading to discontinuation of ustekinumab
[three (12%) and one (04%) patients, respectively] was low.
Table 1 Baseline patient characteristics according to treatment arm
Baseline
characteristica
Arm 1:
ustekinumab with
immediate
methotrexate
withdrawal
(n = 244)
Arm 2:
ustekinumab with
gradual
methotrexate
withdrawal
(n = 245)
Age (years), mean (SD) 45 (12) 47 (13)
Male, n (%) 170 (70) 162 (66)
Weight (kg), mean (SD) 86 (20) 85 (19)
BMI (kg m2), mean (SD) 28 (55) 28 (55)
Diagnosis of
psoriatic arthritis, n (%)
55 (23) 71 (29)
Duration of prior
methotrexate use
(years) (n = 243,
245), n (%)
< 1 147 (61) 139 (57)
≥ 1 and < 3 62 (26) 75 (31)
≥ 3 34 (14) 31 (13)
Methotrexate dose
at screening (mg weekly)
(n = 243, 244),
mean (SD)
146 (38) 144 (41)
Received ≥ 1
previous biologic
(n = 244, 245),b n (%)
73 (30) 67 (27)
PASI (n = 244,
243), median (Q1, Q3)
152 (12, 20) 154 (12, 19)
PGA 0 or 1
(cleared or minimal)
(n = 242, 242),c n (%)
1 (04) 1 (04)
PGA 4 or 5
(marked or severe)
(n = 242, 242), n (%)
64 (26) 58 (24)
DLQI (n = 242, 241),
median (Q1, Q3)
8 (4, 14) 9 (4, 14)
EQ-5D VAS
(n = 190, 197),
median (Q1, Q3)
70 (50, 80) 70 (50, 85)
HADS-A (n = 235,
238), median (Q1, Q3)
5 (3, 8) 5 (3, 9)
HADS-D (n = 233,
238), median (Q1, Q3)
3 (1, 6) 4 (1, 7)
BMI, body mass index; DLQI, Dermatology Life Quality Index;
EQ-5D VAS, EuroQol-5D visual analogue scale; HADS-A, Hospital
Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety
and Depression Scale-Depression; PASI, Psoriasis Area and Sever-
ity Index; PGA, Physician’s Global Assessment; Q1, lower quar-
tile; Q3, upper quartile. aWhere data are not available for all
patients, numbers of patients are given in parentheses for arms 1
and 2, respectively; bincluding infliximab (83 patients), etaner-
cept (64 patients), adalimumab (51 patients), efalizumab (39
patients) and alefacept (1 patient); cone patient in arm 1 had a
PGA score of 1 and a PASI score of 11, one patient in arm 2 had
a PGA score of 1 and a PASI score of 13.
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Fig 1. Median Psoriasis Area and Severity Index (PASI) score at
baseline, week 4 and week 12 after starting ustekinumab in arm 1
(immediate withdrawal of methotrexate) or arm 2 (gradual
methotrexate withdrawal). Values for each data point are shown above
the error bars, and error bars represent interquartile ranges.
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Some investigators reported psoriasis as an AE, based on their
clinical judgement (Table 3), and this was reported more often
for patients in the gradual withdrawal arm than with immediate
withdrawal. Five patients in the gradual withdrawal arm and
two patients in the immediate withdrawal arm had PASI ≥ 25%
higher at week 2 and/or week 4 than at baseline. One patient in
the immediate withdrawal arm experienced psoriasis as an SAE,
but this occurred > 2 months after starting ustekinumab. The
most commonly reported AEs were headache, nasopharyngitis,
arthralgia, hypertension and pruritus. By week 12, no deaths
occurred and the only SAE reported in more than one patient
was abdominal pain, occurring in two patients.
One patient had acute hepatitis B that was classified as an
AE of special interest and a serious infection. After appropriate
treatment, the hepatologist considered the condition under
control and liver biochemistry was normal; a case study is
presented elsewhere.14 No other AEs of special interest, such
as nonmelanoma skin cancer, malignancies or major adverse
cardiovascular events (MACE), were reported by week 12
(Table 3). The incidence of infections was similar irrespective
of the transition strategy used; the majority of these were
minor and did not require treatment with antibiotics
(Table 3). There was no obvious difference between the two
treatment arms in changes in the liver enzymes, alanine ami-
notransferase (ALT) or aspartate aminotransferase (AST). How-
ever, in both arms, a general decrease in ALT was seen. At
baseline, median ALT levels were 28 U L1 in both treatment
arms, decreasing at week 4 (to 25 and 26 U L1 in the
immediate and gradual withdrawal arms, respectively), but
then remaining constant in both arms up to week 12
(25 U L1). Consistent with median change, in both arms
there was a decrease in the proportion of patients with ele-
vated ALT or AST, along with an increase in the proportion of
patients with low ALT or AST (≤ 1 9 the upper limit of nor-
mal) (Fig. 3).
Patient-reported outcomes
Median DLQI was substantially reduced between baseline and
week 16, and a high proportion of patients achieved a ≥ 5-
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Fig 2. Proportion of patients achieving (a) Psoriasis Area and Severity
Index (PASI) score ≤ 1, ≤ 3 or ≤ 5 or (b) a reduction from baseline
of 50% (PASI 50), 75% (PASI 75), 90% (PASI 90) or 100% (PASI
100) at 12 weeks after starting ustekinumab in arm 1 (immediate
withdrawal of methotrexate) or arm 2 (gradual methotrexate
withdrawal). Values for each data point are shown above the error
bars, and error bars represent 95% confidence intervals.
Table 2 Observed and last-observation-carried-forward (LOCF) imputed data for Psoriasis Area and Severity Index (PASI) score and Physician’s
Global Assessment (PGA) at week 12
Arm 1: ustekinumab with immediate
methotrexate withdrawal
Arm 2: ustekinumab with gradual
methotrexate withdrawal
Observed data LOCF imputed data Observed data LOCF imputed data
PASI
n 241 244 238 243
Mean (SD) 44 (50) 46 (53) 42 (43) 44 (44)
95% confidence interval 38–51 39–52 37–48 38–49
Median (Q1, Q3) 29 (08, 63) 29 (09, 65) 28 (11, 58) 28 (12, 60)
Range (min.–max.) 00–33 00–33 00–20 00–20
PGA
n 239 242 236 242
Mean (SD) 12 (09) 14 (09) 12 (08) 12 (09)
95% confidence interval 11–14 11–14 11–13 11–13
Median (Q1, Q3) 10 (10, 20) 10 (10, 20) 10 (10, 20) 10 (10, 20)
Range (min.–max.) 00–40 00–40 00–40 00–40
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point reduction in DLQI or a DLQI of 0 or 1 at week 16, irre-
spective of the transition strategy used (Table 4). EQ-5D VAS
and HADS showed a small improvement by week 16
(Table 4).
Discussion
The TRANSIT study is the first evidence-based assessment of
strategies for transitioning patients with moderate-to-severe
psoriasis from a conventional systemic agent to a biological
agent without a ‘no treatment’ washout period. In patients
with an inadequate response to methotrexate, we showed sim-
ilar efficacy after initiating ustekinumab irrespective of
whether methotrexate was immediately or gradually with-
drawn. Similarly, both an immediate switch from methotrex-
ate to ustekinumab and an overlapping 4-week methotrexate-
tapering strategy were well tolerated, with low discontinuation
rates. Therefore, either immediate or gradual transition is a
feasible approach in patients switching from methotrexate to
ustekinumab. This has important implications for the day-
to-day clinical management of patients, confirming that a
Table 3 Overall safety profile, most common treatment-emergent
adverse events (AEs) and serious AEs (SAEs) at 12 weeks after
initiation of ustekinumab, according to treatment arm
Arm 1:
ustekinumab
with immediate
methotrexate
withdrawal
(n = 244)
Arm 2:
ustekinumab
with gradual
methotrexate
withdrawal
(n = 245)
Overall safety profile
Any AE 149 (61) 158 (65)
Any SAE 7 (29) 6 (24)
Discontinuation of
ustekinumab due to AEsa
3 (12) 1 (04)
Death 0 0
Psoriasis worsening reported as an AE
Psoriasis as an AE 4 (16) 8 (33)
Psoriasis as an SAE
(psoriasis exacerbation)
1 (04) 0
Most commonb AEs by system organ class
Nervous system disorders
Headache 26 (107) 24 (98)
Respiratory, thoracic and mediastinal disorders
Nasopharyngitis 27 (11) 19 (78)
Cough 4 (16) 6 (24)
Rhinitis 4 (16) 6 (24)
Oropharyngeal pain 3 (12) 5 (20)
Musculoskeletal and connective tissue disorders
Arthralgia 15 (61) 14 (57)
Myalgia 4 (16) 6 (24)
Skin and subcutaneous tissue disorders
Pruritus 6 (25) 12 (49)
Generalized pruritus 4 (16) 2 (08)
Gastrointestinal disorders
Diarrhoea 6 (25) 7 (29)
Gastroenteritis 6 (25) 2 (08)
General disorders and administration-site conditions
Pyrexia 1 (04) 7 (29)
Infections and infestations
Oral herpes 2 (08) 5 (20)
Upper respiratory
tract infection
2 (08) 5 (20)
Vascular disorders
Hypertension 11 (45) 12 (49)
Laboratory investigations
Blood creatine
phosphokinase increased
4 (16) 5 (20)
Alanine
aminotransferase increased
1 (04) 5 (20)
SAEsc
Abdominal pain 0 2 (08)
Alcoholism 1 (04) 0
Ankle fracture 1 (04) 0
Deep vein thrombosis 0 1 (04)
Drug hypersensitivityd 0 1 (04)
Foot fracture 1 (04) 0
Headache 1 (04) 0
Hepatitis B 1 (04) 0
Hypertension 0 1 (04)
Joint dislocation 1 (04) 0
Uterine polyp 0 1 (04)
Table 3 (continued)
Arm 1:
ustekinumab
with immediate
methotrexate
withdrawal
(n = 244)
Arm 2:
ustekinumab
with gradual
methotrexate
withdrawal
(n = 245)
AEs of special interest
Serious infectionse 1 (04) 0
Nonmelanoma skin cancer 0 0
Malignancies 0 0
MACEsf 0 0
Infections and infections requiring antibioticsg
Infections 49 (20) 53 (22)
Infections requiring
antibiotics
18 (74) 14 (57)
Data are presented as n (%). MACE, major adverse cardiovascular
event. aDiscontinuation (n = 4) due to: AE temporally associated
with study (n = 1 in each arm); severe injection-site reaction or
infection classified as a serious AE (n = 1 in arm 1), and investi-
gator or sponsor decision (n = 1 in arm 1). bMost common AEs
(by MedDRA preferred term) occurring in ≥ 5 patients in any
treatment group from baseline to week 12 and excluding psoria-
sis. cSAEs from baseline to week 12 and excluding psoriasis.
dThe patient was hospitalized with suspected laryngeal dyspnoea
and cutaneous eruptions, reported by the investigator as induced
by amoxicillin. eOne case of acute hepatitis B, with elevated liver
enzymes detected at study week 2; the patient was negative for
hepatitis B surface antigen antibodies at screening but was not
tested for hepatitis B core antigen antibodies. fMACEs comprise
myocardial infarction, cerebrovascular accident and any-cause
cardiovascular death. gInfections and infections requiring
antibiotics irrespective of whether these were serious enough
to be reported as AEs.
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washout period or methotrexate-tapering strategy are not nec-
essary when switching from methotrexate to ustekinumab in
patients with an inadequate response to methotrexate. The
pragmatic approach tested in this study is closer to real-life
clinical situations than the regimens usually tested in clinical
trials and our data support the simplification of transition
strategies for these patients.
Timing of drug administration in our study should be
noted. After stopping methotrexate, the time to relapse has
been reported as 4–5 weeks15 and the effect of ustekinumab
is rapid.5 This suggests that patients would receive sufficient
exposure to active therapy throughout both the early and later
weeks of ustekinumab treatment, which was supported by this
study. Similarly, in this analysis, the rate of AEs was not
higher among patients who received overlapping treatment
than in patients who stopped methotrexate immediately. This
might be partly because the methotrexate dose was rapidly
reduced in the gradual withdrawal arm. However, our results
do not indicate a need for longer overlap periods.
Overall, the safety and tolerability profile was consistent
with previous ustekinumab studies.2,3,7,16 Very few patients
discontinued treatment before week 12. Methotrexate is
known to be hepatotoxic,17 therefore it is not surprising that
liver enzyme levels tended to decrease during and after with-
drawal of methotrexate. This may also explain why an increase
in ALT tended to be more frequently reported as an AE in the
gradual vs. immediate methotrexate withdrawal arm. Us-
tekinumab showed substantial efficacy at week 12, with 69%,
53% and 27% of patients, overall, achieving an absolute PASI
score ≤ 5, ≤ 3 and ≤ 1, respectively, in this population of
patients with inadequate response to methotrexate at baseline
and of which a notable proportion had received prior biologi-
cal treatment (29%) or a diagnosis of psoriatic arthritis
(26%). A slightly lower proportion (60%) of patients achieved
PASI 75 at week 12 in this study than in the phase III us-
tekinumab clinical trials (64–76% in PHOENIX 1 and 2).2,3
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Fig 3. The proportion of patients with (a) alanine aminotransferase or
(b) aspartate aminotransferase levels according to categories above the
upper limit of normal (ULN) over time from baseline to 12 weeks
after starting ustekinumab in arm 1 (immediate withdrawal of
methotrexate) or arm 2 (gradual methotrexate withdrawal). The
proportion of patients within each of the two lower level categories is
shown within each bar.
Table 4 Patient-reported outcomes at 16 weeks after initiation of
ustekinumab, according to treatment arm
Patient-reported outcome
Arm 1:
ustekinumab
with immediate
methotrexate
withdrawal
Arm 2:
ustekinumab
with gradual
methotrexate
withdrawal
DLQI, median (Q1, Q3)
n 234 238
Baseline 8 (4, 14) 9 (4, 14)
Week 16 1 (0, 4) 1 (0, 4)
DLQI decrease, n (%)
n 234 238
Reduction of ≥ 5
points by week 16a
134 (57) 142 (60)
DLQI 0 or 1, n (%)
n 234 238
Baseline 19 (8) 17 (7)
Week 16 131 (56) 137 (58)
EQ-5D VAS, median (Q1, Q3)
n 189 194
Baseline 70 (50, 80) 70 (50, 85)
Week 16 80 (65, 90) 80 (70, 90)
HADS-Anxiety, median (Q1, Q3)
n 232 237
Baseline 5 (3, 8) 5 (3, 9)
Week 16 4 (2, 8) 4 (2, 7)
HADS-Depression, median (Q1, Q3)
n 231 237
Baseline 3 (1, 6) 4 (1, 7)
Week 16 2 (1, 5) 2 (1, 4)
DLQI, Dermatology Life Quality Index; EQ-5D VAS, EuroQol-5D
visual analogue scale; HADS, Hospital Anxiety and Depression
Scale; Q1, lower quartile; Q3, upper quartile. aAt baseline, 140
patients [70 per arm (each 29%)] had a DLQI score of <5 and,
therefore, could not achieve a DLQI reduction of ≥5.
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This can primarily be explained by differences in baseline PASI
scores due to differences in study design (use of a washout
period in the PHOENIX trials) and inclusion criteria (PASI
threshold ≥ 10 in TRANSIT vs. ≥ 12 in the PHOENIX trials).
As a washout was not used in TRANSIT, baseline PASI may
represent partially treated psoriasis. In addition, all patients in
TRANSIT had previously shown an inadequate response to
methotrexate, and could therefore be considered more treat-
ment refractory than the patients enrolled in the PHOENIX tri-
als. It should also be noted that PASI is not linear18,19 and,
therefore, comparisons of percentage reductions between trials
may have limited validity. Indeed, a similar or higher propor-
tion of patients achieved PGA 0 or 1 at week 12 in this study
(67%) compared with PHOENIX 1 (60–62%) or 2 (68–
73%).2,3 Additionally, it is encouraging to note that during
this 12-week study period there was no increased incidence of
MACE, not inconsistent with the available clinical data,20,21
suggesting neither a detrimental nor a beneficial effect of us-
tekinumab on serious cardiovascular events.
Psoriasis has a negative effect on a patient’s quality of life.22
In TRANSIT, patient-reported outcomes were assessed at week
16 (rather than at week 12) as this is when the third dose is
given, and when the decision to continue treatment is often
made in clinical practice.23 In addition, national healthcare
organizations, such as the U.K. National Institute for Health
and Care Excellence, define stopping rules for ustekinumab at
week 16 on the basis of PASI and DLQI outcomes.24 This is in
contrast to the European Summary of Product Characteristics,7
which states that consideration should be given to discontinu-
ing treatment in the case of nonresponse at week 28. In
TRANSIT, more than half of patients achieved a clinically
meaningful25 ≥ 5-point reduction in DLQI, or a DLQI score of
0 or 1 indicating no effect of the disease at all on the patients’
quality of life26 at week 16, irrespective of the transition strat-
egy used. EQ-5D VAS and HADS both showed a small
improvement from baseline to week 16, but baseline scores
were within or close to the ‘normal’ range for both scales;
population norms for EQ-5D VAS are around 72–83 for Euro-
pean countries,12 and a HADS of ≥ 8 on either scale can be
considered clinically relevant anxiety/depression.13 By this
definition, approximately one-quarter of patients in TRANSIT
had clinically relevant anxiety and/or depression at baseline, a
similar proportion to that reported in PHOENIX 2.27
Although our findings are useful in the clinical setting, this
study has some limitations: a nonustekinumab comparator
arm was not included; psoriatic arthritis was not assessed dur-
ing the trial; there was no dose-adjustment possibility for
patients weighing > 100 kg in this study; the planned sample
size of 576 patients was not reached and, therefore, statistical
power to detect a difference between treatment arms would
be limited; we cannot exclude the possibility that different
transition strategies and inclusion or exclusion criteria would
yield different results; and we collected only categorical data
on the duration of prior methotrexate use (< 1 year, 1 to
< 3 years and ≥ 3 years). In addition, as there was no wash-
out, it is possible that the baseline PASI score (absolute) could
have been influenced by prior treatment with methotrexate.
Finally, albeit not addressed in this study, adding ustekinumab
to methotrexate may be a potential option for patients, and
examining this combination in the long-term could be mer-
ited.
Taken together, our data demonstrate that either an imme-
diate or a gradual transition from methotrexate to us-
tekinumab is a feasible approach in patients with an
inadequate response to methotrexate; a washout period or
methotrexate-tapering strategy is not necessary. Ustekinumab
showed favourable efficacy and tolerability, irrespective of
whether methotrexate was immediately or gradually with-
drawn. Both of these transition scenarios are highly relevant in
day-to-day clinical practice.
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